Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018

  • ID: 4540572
  • Report
  • 406 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AB Science SA
  • Array BioPharma Inc
  • Calithera Biosciences Inc
  • Exelixis Inc
  • Loxo Oncology Inc
  • Novartis AG
  • MORE
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights:

This latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 15, 17, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science SA
  • Array BioPharma Inc
  • Calithera Biosciences Inc
  • Exelixis Inc
  • Loxo Oncology Inc
  • Novartis AG
  • MORE
Introduction

Gastrointestinal Stromal Tumor (GIST) - Overview

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment

Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development

Gastrointestinal Stromal Tumor (GIST) - Drug Profiles

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects

Gastrointestinal Stromal Tumor (GIST) - Discontinued Products

Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Bayer AG, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Co, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Loxo Oncology Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Merck & Co Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Merck KGaA, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pfizer Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Soricimed Biopharma Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Pipeline by Xencor Inc, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2018

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AB Science SA
  • Ariad Pharmaceuticals Inc
  • Arog Pharmaceuticals Inc
  • ArQule Inc
  • Array BioPharma Inc
  • Ascentage Pharma Group Corp Ltd
  • Bayer AG
  • Blueprint Medicines Corp
  • Boston Biomedical Inc
  • Calithera Biosciences Inc
  • Celldex Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • Daiichi Sankyo Co Ltd
  • Deciphera Pharmaceuticals LLC
  • Eli Lilly and Co
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Horizon Pharma Plc
  • Immunicum AB
  • Jiangsu Hengrui Medicine Co Ltd
  • Loxo Oncology Inc
  • Merck & Co Inc
  • Merck KGaA
  • Natco Pharma Ltd
  • Nerviano Medical Sciences Srl
  • Novartis AG
  • Omeros Corp
  • Pfizer Inc
  • Pharma Mar SA
  • Plexxikon Inc
  • Rhizen Pharmaceuticals SA
  • Soricimed Biopharma Inc
  • Taiho Pharmaceutical Co Ltd
  • Xencor Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll